A Phase 3 interventional study of Ibrutinib and Next-line ibrutinib in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, sponsored by Pharmacyclics LLC.. Completed at 88 sites in 16 countries. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2024-09-19.
Sponsored by Pharmacyclics LLC. (part of AbbVie) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell — 8 open to participants now, 28 under way, 4 of them phase 3. ibrutinib · Leukemia, Lymphocytic, Chronic, B-Cell.
Among the 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 10th largest by enrollment, is one of 7 that started in 2013, is one of 14 in phase 3, and was the 12th registered.
2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.
Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →8 of the 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 12 countries. Recruiting first, the newest first:
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 18–80
Gruppo Italiano Malattie EMatologiche dell'Adulto · Sites in Italy
Ages 18+
Paolo Ghia · Sites in Italy
Ages 18–65
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18–75
Jeanette Lundin · Sites in Norway, Sweden
Ages 18+
By country, each count listing its studies:
ibrutinib: first FDA approval 2013 (IMBRUVICA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
83 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 51 · Phase 3 15 · Phase 4 1
First in 2010; this study’s year is marked. 7 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 269 is above the median of 39 across 1,603 interventional studies indexed under Leukemia, Lymphocytic, Chronic, B-Cell.
Median enrollment 44 across the 83 interventional studies. Of the 44 that completed or were terminated, 26 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 83 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pharmacyclics LLC., one of the names counted as AbbVie. Under that name alone:
Pharmacyclics LLC. is the lead sponsor of 54 studies on the registry; none are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 9 (90%) have results posted.
51 studies in Leukemia, Lymphocytic, Chronic, B-Cell by AbbVie: 3 open now, 11 under way, 2 of them phase 3. Of 38 finished, 18 (47%) have results posted.
Among the 51 studies in Leukemia, Lymphocytic, Chronic, B-Cell by AbbVie, this one is the 3rd largest by enrollment of the 39 interventional ones that give a count, is one of 4 that started in 2013, is one of 9 in phase 3, and was the 19th registered.
AbbVie’s Leukemia, Lymphocytic, Chronic, B-Cell studies by the year they started, since 2004.
6 of the studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01804686Phase 3Janssen Research & Development, LLCA Long-term Extension Study of PCI-32765 (Ibrutinib) | 2026-12-31 |
| NCT03513562Ohio State University Comprehensive Cancer CenterVenetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance Mutations | 2026-12-31 |
| NCT03153202Joshua BrodyStudy to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL) | 2027-04 |
| NCT03960840Novartis PharmaceuticalsPhase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL | 2027-06-30 |
| NCT02756897M.D. Anderson Cancer CenterVenetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia | 2027-07-01 |
Add all 6 to your calendar (.ics) → With an account.
Among the 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, from their registry updates:
Among AbbVie’s 51 in Leukemia, Lymphocytic, Chronic, B-Cell:
This tab as a report to print or save as PDF → With an account.
An Open-label Extension Study in Patients 65 Years or Older with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Participated in Study PCYC-1115-CA (Ibrutinib versus Chlorambucil)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants who received chlorambucil 0.5 mg/kg (to maximum 0.8 mg/kg) Days 1 and 15 of 28-day cycle up to 12 cycles in Study 1115. In Study 1116, participants had the option to crossover to next-line ibrutinib 420 mg/day after disease progression (PD).
Drug: Ibrutinib
Participants who received ibrutinib 420 mg daily in Study 1115 received ibrutinib orally once daily. Participants continuing in first-line ibrutinib therapy entered Study 1116 at the ibrutinib dose tolerated in Study 1115.
Drug: Next-line ibrutinib
Ibrutinib 420 mg (3 x 140-mg capsules) is administered orally once daily
Also known as: PCI-32765
Ibrutinib 420 mg (3 x 140-mg capsules) is administered orally once daily
Also known as: PCI-32765
Progression Free Survival (PFS) Based on Investigator Assessment
PFS is defined as the time from the date of randomization to the date of disease progression determined by the investigator or date of death from any cause, whichever occurs first, regardless of the use of subsequent antineoplastic therapy prior to disease progression (PD) or death. Estimated by Kaplan-Meier method.
Time frame: Median overall follow-up of 82.7 months
Progression Free Survival After Initiation of Subsequent Anticancer Therapy (PFS2)
PFS2 is defined as the time from the date of randomization to the earliest occurrence of the following three types of events: * PD per investigator response assessment after initiation of the first subsequent anti-cancer therapy * Initiation of second subsequent anti-cancer therapy * Death due to any cause, regardless of administration of subsequent anticancer therapy. Kaplan-Meier landmark estimate of the PFS2 rate at 60 months (that is, the estimated percentage of participants with PFS2 at Month 60) is presented.
Time frame: Median overall follow-up of 82.7 months
Overall Survival (OS)
OS is defined as the time from randomization to death due to any cause. Kaplan-Meier landmark estimate of the OS rate at 60 months (that is, the estimated percentage of participants with OS at Month 60) is presented.
Time frame: Median overall follow-up of 82.7 months
Time to Next Treatment (TTNT)
Time from randomization to initiation of any subsequent treatment for chronic lymphocytic leukemia (CLL).
Time frame: Median overall follow-up of 82.7 months
Overall Response Rate (ORR)
ORR is defined as the percentage of participants who achieve complete response (CR), complete response with an incomplete marrow recovery (CRi), nodular partial response (nPR), or partial response (PR), as determined by the investigator at or prior to initiation of subsequent antineoplastic therapy according to the International Workshop on CLL (iwCLL) 2008 criteria with the 2012 iwCLL modification stating that treatment-related lymphocytosis in the setting of improvement in other parameters was not considered as PD and the 2013 iwCLL clarification of criteria for a partial response to therapy.
Time frame: Median overall follow-up of 82.7 months
Rate of Minimal Residual Disease (MRD) Negativity
Percentage of participants who achieved MRD-negative response defined as \< 1 CLL cell per 10,000 leukocytes as assessed by flow cytometry of a bone marrow aspirate and/or peripheral blood sample per central laboratory at or prior to initiation of subsequent antineoplastic therapy.
Time frame: Median overall follow-up of 82.7 months
Duration of Response (DOR)
DOR will be calculated for the participants achieving a protocol-defined response (Halleck 2008; CR, CRi, nPR, PR) per investigator assessment and is defined as time from the date of initial response including PR with lymphocytosis to the date of disease progression or the date of death from any cause, whichever occurs first.
Time frame: Median overall follow-up of 82.7 months
This extension study provided ongoing treatment and follow-up for participants previously enrolled in the parent study (PCYC-1115-CA; Study 1115; NCT01722487). Participants entered this study upon Independent Review Committee (IRC)-confirmed progressive disease (PD) or the closure of Study 1115, whichever was earlier.
| Milestone | Ibrutinib | Chlorambucil |
|---|---|---|
| Started | 136 | 133 |
| Received next-line ibrutinib after pd | 0 | 78 |
| Completed | 57 | 63 |
| Not completed | 79 | 70 |
| Withdrew: Death | 42 | 42 |
| Withdrew: Lost to follow-up | 5 | 1 |
| Withdrew: Withdrawal by subject | 27 | 19 |
| Withdrew: Did not rollover from parent study | 5 | 8 |
PFS is defined as the time from the date of randomization to the date of disease progression determined by the investigator or date of death from any cause, whichever occurs first, regardless of the use of subsequent antineoplastic therapy prior to disease progression (PD) or death. Estimated by Kaplan-Meier method.
| months | Ibrutinib | Chlorambucil |
|---|---|---|
| Progression Free Survival (PFS) Based on Investigator Assessment | 106.9 (83.4 to NA) | 15.0 (10.2 to 19.4) |
PFS2 is defined as the time from the date of randomization to the earliest occurrence of the following three types of events: * PD per investigator response assessment after initiation of the first subsequent anti-cancer therapy * Initiation of second subsequent anti-cancer therapy * Death due to any cause, regardless of administration of subsequent anticancer therapy. Kaplan-Meier landmark estimate of the PFS2 rate at 60 months (that is, the estimated percentage of participants with PFS2 at Month 60) is presented.
| percentage of participants | Ibrutinib | Chlorambucil |
|---|---|---|
| Progression Free Survival After Initiation of Subsequent Anticancer Therapy (PFS2) | 79.3 (71.1 to 85.4) | 58.4 (48.8 to 66.7) |
OS is defined as the time from randomization to death due to any cause. Kaplan-Meier landmark estimate of the OS rate at 60 months (that is, the estimated percentage of participants with OS at Month 60) is presented.
| percentage of participants | Ibrutinib | Chlorambucil |
|---|---|---|
| Overall Survival (OS) | 82.8 (75.0 to 88.3) | 68.4 (59.1 to 75.9) |
Time from randomization to initiation of any subsequent treatment for chronic lymphocytic leukemia (CLL).
| months | Ibrutinib | Chlorambucil |
|---|---|---|
| Time to Next Treatment (TTNT) | NA (NA to NA) | 25.1 (21.8 to 27.9) |
ORR is defined as the percentage of participants who achieve complete response (CR), complete response with an incomplete marrow recovery (CRi), nodular partial response (nPR), or partial response (PR), as determined by the investigator at or prior to initiation of subsequent antineoplastic therapy according to the International Workshop on CLL (iwCLL) 2008 criteria with the 2012 iwCLL modification stating that treatment-related lymphocytosis in the setting of improvement in other parameters was not considered as PD and the 2013 iwCLL clarification of criteria for a partial response to therapy.
| percentage of participants | Ibrutinib | Chlorambucil |
|---|---|---|
| Overall Response Rate (ORR) | 91.2 | 36.8 |
Percentage of participants who achieved MRD-negative response defined as \< 1 CLL cell per 10,000 leukocytes as assessed by flow cytometry of a bone marrow aspirate and/or peripheral blood sample per central laboratory at or prior to initiation of subsequent antineoplastic therapy.
| percentage of participants | Ibrutinib | Chlorambucil |
|---|---|---|
| Rate of Minimal Residual Disease (MRD) Negativity | 5.1 | 0 |
DOR will be calculated for the participants achieving a protocol-defined response (Halleck 2008; CR, CRi, nPR, PR) per investigator assessment and is defined as time from the date of initial response including PR with lymphocytosis to the date of disease progression or the date of death from any cause, whichever occurs first.
| months | Ibrutinib | Chlorambucil |
|---|---|---|
| Duration of Response (DOR) | NA (84.0 to NA) | 29.7 (15.2 to 40.4) |
Collected over All-cause mortality: median overall follow-up of 82.7 months. Adverse events: from first dose of any study treatment to 30 days after last dose of study treatment or initiation of subsequent therapy whichever was earlier. Median treatment duration was: 74.0 months for Ibrutinib arm; 7.1 months for Chlorambucil arm; 26.9 months for Crossover Next-line Ibrutinib arm.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ibrutinib | 42/135 (31.1%) | 111/135 (82.2%) | 134/135 (99.3%) |
| Chlorambucil | 44/132 (33.3%) | 33/132 (25%) | 120/132 (90.9%) |
| Next-line Ibrutinib After PD on Chlorambucil | 24/78 (30.8%) | 49/78 (62.8%) | 75/78 (96.2%) |
| Event | Ibrutinib | Chlorambucil | Next-line Ibrutinib After PD on Chlorambucil |
|---|---|---|---|
| PNEUMONIAInfections and infestations | 27/135 | 2/132 | 7/78 |
| ATRIAL FIBRILLATIONCardiac disorders | 11/135 | 1/132 | 6/78 |
| BASAL CELL CARCINOMANeoplasms benign, malignant and unspecified (incl cysts and polyps) | 9/135 | 0/132 | 1/78 |
| URINARY TRACT INFECTIONInfections and infestations | 6/135 | 0/132 | 5/78 |
| ABDOMINAL PAINGastrointestinal disorders | 1/135 | 0/132 | 3/78 |
| PYREXIAGeneral disorders | 4/135 | 5/132 | 1/78 |
| CARDIAC FAILURECardiac disorders | 5/135 | 0/132 | 1/78 |
| SEPSISInfections and infestations | 5/135 | 0/132 | 0/78 |
| HYPONATRAEMIAMetabolism and nutrition disorders | 5/135 | 0/132 | 0/78 |
| SYNCOPENervous system disorders | 5/135 | 2/132 | 1/78 |
| Event | Ibrutinib | Chlorambucil | Next-line Ibrutinib After PD on Chlorambucil |
|---|---|---|---|
| DIARRHOEAGastrointestinal disorders | 67/135 | 22/132 | 27/78 |
| FATIGUEGeneral disorders | 55/135 | 51/132 | 18/78 |
| NAUSEAGastrointestinal disorders | 43/135 | 52/132 | 13/78 |
| COUGHRespiratory, thoracic and mediastinal disorders | 52/135 | 20/132 | 19/78 |
| ARTHRALGIAMusculoskeletal and connective tissue disorders | 41/135 | 10/132 | 22/78 |
| OEDEMA PERIPHERALGeneral disorders | 39/135 | 11/132 | 15/78 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 38/135 | 23/132 | 20/78 |
| HYPERTENSIONVascular disorders | 37/135 | 0/132 | 10/78 |
| PYREXIAGeneral disorders | 36/135 | 14/132 | 9/78 |
| WEIGHT DECREASEDInvestigations | 34/135 | 16/132 | 12/78 |
| Age, Continuous(years) | Ibrutinib | Chlorambucil | Total |
|---|---|---|---|
| Mean | 73.1 ± 5.67 | 73.4 ± 5.95 | 73.3 ± 5.81 |
| Sex: Female, Male(Participants) | Ibrutinib | Chlorambucil | Total |
|---|---|---|---|
| Female | 48 | 52 | 100 |
| Male | 88 | 81 | 169 |
| Ethnicity (NIH/OMB)(Participants) | Ibrutinib | Chlorambucil | Total |
|---|---|---|---|
| Hispanic or Latino | 3 | 2 | 5 |
| Not Hispanic or Latino | 132 | 129 | 261 |
| Unknown or Not Reported | 1 | 2 | 3 |
| Race/Ethnicity, Customized(Participants) | Ibrutinib | Chlorambucil | Total |
|---|---|---|---|
| White | 120 | 125 | 245 |
| Asian | 9 | 4 | 13 |
| Black or African American | 5 | 3 | 8 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Subject declined to answer/unknown | 2 | 0 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Requests for access to individual participant data from clinical studies conducted by Pharmacyclics LLC, an AbbVie Company, can be submitted through Yale Open Data Access (YODA) Project site at the following link.
Data sharing details ↗ · yoda.yale.edu
Ran from Dec 2013 to primary completion in Aug 2023, 116 months.
Results were first posted in Sep 2024, 1 year 1 month after primary completion.
Of 57 industry-sponsored phase 3 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 73. This study's 116 months is above that.
Counting every sponsor, half of 83 studies reached it within 59 months; a quarter within 43 and three quarters within 76.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ibrutinib
Leukemia, Lymphocytic, Chronic, B-Cell →